The Challenges and Novel Approaches in the Nanoparticle Formulation of DPP Inhibitors
1, 1, 2, 3
- 1Department of Pharmaceutics, School of Pharmacy, Sri Balaji Vidyapeeth (Deemed to be University), Puducherry Campus, Puducherry, Tamil Nadu, India.
- 2Department of Biotechnology, Faculty of Medicine and Bioscience, MAHSA University, Bandar Saujana Putra, Jenjarom, Selangor Darul Ehsan, Malaysia.
- 3Department of Biotechnology, Faculty of Pharmacy, Lincoln University, Petaling Jaya, Sunway City, Malaysia.
CORRESPONDENCE
Dr. Sundaramoorthi Revathi
Professor, Department of Pharmaceutics, School of Pharmacy, Sri Balaji Vidyapeeth (Deemed to be University), Puducherry Campus, Puducherry, INDIA.
Received: 03-10-2025; Revised: 28-01-2025; Accepted: 18-03-2025.
Volume 14, Issue 1 · pp. 18-22 · 2025 · DOI: 10.5530/ajbls.20251309
ABSTRACT
Drug delivery methods based on nanoparticles have shown great promise in the effective administration of medicinal drugs, such as inhibitors of Dipeptidyl Peptidase (DPP). In the treatment of type 2 diabetes, DPP inhibitors are commonly used, and their formulation as nanoparticles offers numerous advantages, such as enhanced bioavailability, controlled release, and targeted delivery. However, several challenges exist in formulating DPP inhibitors into nanoparticles, including drug stability, particle size control, and sustained release kinetics. This review article aims to discuss the challenges associated with nanoparticle formulation of DPP inhibitors and highlight recent innovative approaches to overcome these limitations.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Saravanan, J., Revathi, S., Ponnaiah, P., & Eden, V. R. (2025). The Challenges and Novel Approaches in the Nanoparticle Formulation of DPP Inhibitors. Asian Journal of Biological and Life Sciences, 14(1), 18-22. https://doi.org/10.5530/ajbls.20251309
Copyright and licence
© 2025 Author(s)
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited. CC BY 4.0
